PAM Stock Recent News

CRNC, PAM and MHO made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 19, 2024.

Pampa (PAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Does Pampa Energia (PAM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.

Pampa Energia's 2Q24 results show stagnation in key segments, with minor growth and significant tariff adjustments for equity holdings but no new expansion plans. Despite a 20% stock appreciation, PAM remains fairly valued with limited growth potential due to infrastructure constraints and political uncertainties, maintaining a Hold rating. The gas and oil segments face production challenges, with no new projects in power generation and an $80 million impairment loss imposed by the government.

Pampa (PAM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ad Hoc Announcement Pursuant to Art. 53 LR  Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.

In a rare occurrence, a 22-year-old man died of primary amoebic meningoencephalitis (PAM) in Pakistan's Karachi, taking the tally of casualties to three this year, ARY News reported...